

Antiviral agents active against influenza A viruses

Nature Reviews Drug Discovery

5, 1015-1025

DOI: [10.1038/nrd2175](https://doi.org/10.1038/nrd2175)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Antivirals and the Control of Influenza Outbreaks. <i>Clinical Infectious Diseases</i> , 2007, 45, 1362-1368.	2.9	48
3	PI3K signalling during influenza A virus infections. <i>Biochemical Society Transactions</i> , 2007, 35, 186-187.	1.6	31
4	Influenza defense: expanding our arsenal with peptide antivirals. <i>Future Virology</i> , 2007, 2, 231-233.	0.9	1
5	Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 280-285.	4.0	57
6	Clinical review: Update of avian influenza A infections in humans. <i>Critical Care</i> , 2007, 11, 209.	2.5	34
7	Non-carbohydrate Inhibitors of the Lectin DC-SIGN. <i>Journal of the American Chemical Society</i> , 2007, 129, 12780-12785.	6.6	113
8	Synthesis of Tamiflu and its Phosphonate Congeners Possessing Potent Anti-Influenza Activity. <i>Journal of the American Chemical Society</i> , 2007, 129, 11892-11893.	6.6	200
9	Thioglycoligase-Based Assembly of Thiodisaccharides: Screening as β -Galactosidase Inhibitors. <i>ChemBioChem</i> , 2007, 8, 1495-1499.	1.3	34
10	Design and synthesis of bioactive adamantane spiro heterocycles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4358-4362.	1.0	90
11	The design of drugs for HIV and HCV. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 1001-1018.	21.5	377
12	Synthesis and medical applications of oligosaccharides. <i>Nature</i> , 2007, 446, 1046-1051.	13.7	656
13	Homology modeling and examination of the effect of the D92E mutation on the H5N1 nonstructural protein NS1 effector domain. <i>Journal of Molecular Modeling</i> , 2007, 13, 1237-1244.	0.8	45
14	Synthesis of acyclic nucleosides based on 1,2,4-triazolo[3,2-c][1,2,4]triazin-7-ones. <i>Russian Chemical Bulletin</i> , 2008, 57, 2423-2430.	0.4	4
15	Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. <i>Proteins: Structure, Function and Bioinformatics</i> , 2008, 71, 1908-1918.	1.5	43
16	The discovery of antiviral agents: Ten different compounds, ten different stories. <i>Medicinal Research Reviews</i> , 2008, 28, 929-953.	5.0	71
17	In vitro anti-influenza screening of several Euphorbiaceae species: Structure of a bioactive Cyanoglucoside from <i>Codiaeum variegatum</i> . <i>Phytochemistry</i> , 2008, 69, 2815-2819.	1.4	19
18	Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 9925-9936.	1.4	33
19	A facile and effective synthesis of lipophilic 2,6-diketopiperazine analogues. <i>Tetrahedron</i> , 2008, 64, 6749-6754.	1.0	15

#	ARTICLE	IF	CITATIONS
20	Design and synthesis of bioactive 1,2-annulated adamantane derivatives. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 3177.	1.5	35
21	Novel Druggable Hot Spots in Avian Influenza Neuraminidase H5N1 Revealed by Computational Solvent Mapping of a Reduced and Representative Receptor Ensemble. <i>Chemical Biology and Drug Design</i> , 2008, 71, 106-116.	1.5	97
22	Structural basis for the function and inhibition of an influenza virus proton channel. <i>Nature</i> , 2008, 451, 596-599.	13.7	549
23	The structural basis for cap binding by influenza virus polymerase subunit PB2. <i>Nature Structural and Molecular Biology</i> , 2008, 15, 500-506.	3.6	436
24	Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock. <i>Antiviral Research</i> , 2008, 78, 170-178.	1.9	42
25	Current and future antiviral therapy of severe seasonal and avian influenza. <i>Antiviral Research</i> , 2008, 78, 91-102.	1.9	210
26	Molecular strategies to inhibit the replication of RNA viruses. <i>Antiviral Research</i> , 2008, 78, 9-25.	1.9	117
27	In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. <i>Antiviral Research</i> , 2008, 79, 199-205.	1.9	24
28	Novel Approaches for Glycodrug Discovery. , 2008, , 2379-2397.		1
29	Carbohydrate-based experimental therapeutics for cancer, HIV/AIDS and other diseases. <i>Acta Histochemica</i> , 2008, 110, 6-13.	0.9	36
30	Genetic diversity-independent neutralization of pandemic viruses (e.g. HIV), potentially pandemic (e.g.) Tj ETQq0 0 0 rgBT /Overlock 107 bioterrorism (variola) by enveloped virus neutralizing compounds (EVNCs). <i>Vaccine</i> , 2008, 26, 3055-3058.	1.7	59
31	Synthesis of sialoclusters appended to calix[4]arene platforms via multiple azide-alkyne cycloaddition. New inhibitors of hemagglutination and cytopathic effect mediated by BK and influenza A viruses. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 1396.	1.5	81
32	Potent inhibition of human influenza H5N1 virus by oligonucleotides derived by SELEX. <i>Biochemical and Biophysical Research Communications</i> , 2008, 366, 670-674.	1.0	83
33	Emerging antiviral drugs. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 393-416.	1.0	40
34	Antivirals for Influenza: Novel Agents and Approaches. , 2008, , 179-192.		1
35	Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17736-17741.	3.3	273
36	Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations. <i>Journal of Chemical Theory and Computation</i> , 2008, 4, 1526-1540.	2.3	67
37	The Cotranslational Maturation Program for the Type II Membrane Glycoprotein Influenza Neuraminidase. <i>Journal of Biological Chemistry</i> , 2008, 283, 33826-33837.	1.6	48

#	ARTICLE	IF	CITATIONS
38	Sensitivity of H5N1 influenza viruses to oseltamivir: an update. <i>Future Virology</i> , 2008, 3, 157-165.	0.9	4
39	Medical Management of Influenza Infection. <i>Annual Review of Medicine</i> , 2008, 59, 397-413.	5.0	125
40	Therapeutic Activity of an Anti-Idiotypic Antibody-Derived Killer Peptide against Influenza A Virus Experimental Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4331-4337.	1.4	28
41	Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3889-3897.	1.4	114
42	High-Throughput Screening of a 100,000-Compound Library for Inhibitors of Influenza A Virus (H3N2). <i>Journal of Biomolecular Screening</i> , 2008, 13, 879-887.	2.6	40
43	Antivirals: current state of the art. <i>Future Virology</i> , 2008, 3, 393-405.	0.9	30
44	Clarithromycin Inhibits Progeny Virus Production from Human Influenza Virus-Infected Host Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 217-222.	0.6	38
45	Identification of a PA-Binding Peptide with Inhibitory Activity against Influenza A and B Virus Replication. <i>PLoS ONE</i> , 2009, 4, e7517.	1.1	75
46	Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?. <i>Clinical Infectious Diseases</i> , 2009, 48, S3-S13.	2.9	239
47	Target Analysis of the Experimental Measles Therapeutic AS-136A. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3860-3870.	1.4	31
48	Potential Targets and Their Relevant Inhibitors in Anti-influenza Fields. <i>Current Medicinal Chemistry</i> , 2009, 16, 3716-3739.	1.2	37
49	Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection. <i>Journal of Virology</i> , 2009, 83, 7151-7165.	1.5	163
50	Pandemic Influenza Vaccines – The Challenges. <i>Viruses</i> , 2009, 1, 1089-1109.	1.5	16
51	Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. <i>Antiviral Research</i> , 2009, 81, 132-140.	1.9	244
52	Anti-influenza virus activity and structure–activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains. <i>Antiviral Research</i> , 2009, 82, 89-94.	1.9	49
53	Another ten stories in antiviral drug discovery (part C): –old and –new– antivirals, strategies, and perspectives. <i>Medicinal Research Reviews</i> , 2009, 29, 611-645.	5.0	77
54	Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paradržions. <i>Medicinal Research Reviews</i> , 2010, 30, 667-707.	5.0	27
55	Oligonucleotides derived from the packaging signal at the 5' end of the viral PB2 segment specifically inhibit influenza virus in vitro. <i>Archives of Virology</i> , 2009, 154, 821-832.	0.9	19

#	ARTICLE	IF	CITATIONS
56	Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. <i>Amino Acids</i> , 2009, 37, 725-732.	1.2	40
57	Case files of the Program in Medical Toxicology at Brown University: Amantadine withdrawal and the neuroleptic malignant syndrome. <i>Journal of Medical Toxicology</i> , 2009, 5, 92-98.	0.8	9
58	NIS-promoted guanylation of amines. <i>Tetrahedron Letters</i> , 2009, 50, 1463-1465.	0.7	27
59	Synthesis of 1,2-annulated adamantane heterocycles: structural determination studies of a bioactive cyclic sulfite. <i>Tetrahedron Letters</i> , 2009, 50, 2671-2675.	0.7	11
60	Structure-function studies of the influenza virus RNA polymerase PA subunit. <i>Science in China Series C: Life Sciences</i> , 2009, 52, 450-458.	1.3	28
61	Systems-based candidate genes for human response to influenza infection. <i>Infection, Genetics and Evolution</i> , 2009, 9, 1148-1157.	1.0	26
62	Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1534-1541.	1.4	44
63	Synthesis and pharmacological evaluation of (2-oxadamant-1-yl)amines. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3198-3206.	1.4	22
64	Neuraminidase inhibitory activities of flavonols isolated from <i>Rhodiola rosea</i> roots and their in vitro anti-influenza viral activities. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6816-6823.	1.4	173
65	Inhibition of viral group-1 and group-2 neuraminidases by oseltamivir: A comparative structural analysis by the ScrewFit algorithm. <i>Biophysical Chemistry</i> , 2009, 141, 117-123.	1.5	8
66	How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants?. <i>Biophysical Chemistry</i> , 2009, 145, 29-36.	1.5	25
67	Structural Basis of the Influenza A Virus RNA Polymerase PB2 RNA-binding Domain Containing the Pathogenicity-determinant Lysine 627 Residue. <i>Journal of Biological Chemistry</i> , 2009, 284, 6855-6860.	1.6	86
68	Synergistic Effect of Zanamivir [®] Porphyrin Conjugates on Inhibition of Neuraminidase and Inactivation of Influenza Virus. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4903-4910.	2.9	50
69	Virtual screening pipeline and ligand modelling for H5N1 neuraminidase. <i>Biochemical and Biophysical Research Communications</i> , 2009, 383, 445-449.	1.0	17
70	Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. <i>Biochemical and Biophysical Research Communications</i> , 2009, 385, 390-394.	1.0	60
71	Discovery of Spiro-Piperidine Inhibitors and Their Modulation of the Dynamics of the M2 Proton Channel from Influenza A Virus. <i>Journal of the American Chemical Society</i> , 2009, 131, 8066-8076.	6.6	87
72	HA-Pseudotyped Retroviral Vectors for Influenza Antagonist Screening. <i>Journal of Biomolecular Screening</i> , 2009, 14, 294-302.	2.6	12
73	Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 2323-2332.	2.5	49

#	ARTICLE	IF	CITATIONS
74	Inhibitory effect of small interfering RNA specific for a novel candidate target in PB1 gene of influenza A virus. <i>Journal of Drug Targeting</i> , 2009, 17, 133-139.	2.1	4
75	Characterizing Loop Dynamics and Ligand Recognition in Human- and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations. <i>Journal of the American Chemical Society</i> , 2009, 131, 4702-4709.	6.6	129
76	Oseltamivir for treatment and prophylaxis of influenza infection. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 357-371.	1.0	42
77	Chapter 1 Looking Back in 2009 at the Dawning of Antiviral Therapy Now 50 Years Ago. <i>Advances in Virus Research</i> , 2009, 73, 1-53.	0.9	30
78	Antiviral chemotherapy in 2009:quo vadis?. <i>Future Virology</i> , 2009, 4, 313-315.	0.9	0
79	Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. <i>Antiviral Therapy</i> , 2010, 15, 1151-1159.	0.6	86
81	Reuse, recycle, reweigh: Combating influenza through efficient sequential Bayesian computation for massive data. <i>Annals of Applied Statistics</i> , 2010, 4, 1722-1748.	0.5	9
82	Coupling the Petasis Condensation to an Iron(III) Chloride-Promoted Cascade Provides a Short Synthesis of Relenza Congeners. <i>Organic Letters</i> , 2010, 12, 5322-5325.	2.4	37
83	Novel Inhibitors of Influenza Virus Fusion: Structure-Activity Relationship and Interaction with the Viral Hemagglutinin. <i>Journal of Virology</i> , 2010, 84, 4277-4288.	1.5	137
84	Distinction and quantitation of sugar isomers in ternary mixtures using the kinetic method. <i>Journal of the American Society for Mass Spectrometry</i> , 2010, 21, 60-67.	1.2	24
85	New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 46-57.	1.4	19
86	Antiviral Action of Methylated Î²-Lactoglobulin on the Human Influenza Virus A Subtype H3N2. <i>Probiotics and Antimicrobial Proteins</i> , 2010, 2, 104-111.	1.9	14
87	Bifunctional Polymeric Inhibitors of Human Influenza A Viruses. <i>Pharmaceutical Research</i> , 2010, 27, 259-263.	1.7	31
88	Viruses as vesicular carriers of the viral genome: A functional module perspective. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 507-519.	1.9	9
89	Evidence Obtained from anova to Reason Cross-species Infection and Cross-subtype Mutation in Neuraminidases of Influenza A Viruses. <i>Transboundary and Emerging Diseases</i> , 2010, 57, no-no.	1.3	7
90	Heterodimers of Histidine and Amantadine as Inhibitors for Wild Type and Mutant M2 Channels of Influenza A. <i>Chinese Journal of Chemistry</i> , 2010, 28, 1417-1423.	2.6	6
91	Pharmacoepial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 853-857.	1.4	23
92	Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. <i>Computational Biology and Chemistry</i> , 2010, 34, 97-105.	1.1	22

#	ARTICLE	IF	CITATIONS
93	Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5379-5390.	1.4	38
94	Inhibition of neuraminidase activity by polyphenol compounds isolated from the roots of <i>Glycyrrhiza uralensis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 971-974.	1.0	82
95	Discovery of novel 1-phenyl-cycloalkane carbamides as potent and selective influenza fusion inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3507-3510.	1.0	13
96	New stilbenoid with inhibitory activity on viral neuraminidases from <i>Erythrina addisoniae</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6430-6434.	1.0	30
97	Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 536-541.	2.6	20
98	Design and synthesis of bioactive adamantan aminoalcohols and adamantan amines. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 5022-5030.	2.6	31
99	Oseltamivir Treatment Prevents the Increased Influenza Virus Disease Severity and Lethality Occurring in Chronic Ethanol Consuming Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2010, 34, 1425-1431.	1.4	11
100	Broad-spectrum antiviral effect of <i>Agrimonia pilosa</i> extract on influenza viruses. <i>Microbiology and Immunology</i> , 2010, 54, 11-19.	0.7	67
101	Human host factors required for influenza virus replication. <i>Nature</i> , 2010, 463, 813-817.	13.7	755
103	Avian influenza pandemic preparedness: developing pre-pandemic and pandemic vaccines against a moving target. <i>Expert Reviews in Molecular Medicine</i> , 2010, 12, e14.	1.6	23
105	Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11531-11536.	3.3	363
106	Antiviral Strategies for Pandemic and Seasonal Influenza. <i>Viruses</i> , 2010, 2, 1766-1781.	1.5	11
107	Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 171-177.	1.0	19
108	Influenza pathogenesis: Lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. <i>Critical Care Medicine</i> , 2010, 38, e21-e29.	0.4	21
109	Current Advances in Anti-Influenza Therapy. <i>Current Medicinal Chemistry</i> , 2010, 17, 2101-2140.	1.2	52
110	Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. <i>Nature Communications</i> , 2010, 1, 113.	5.8	102
111	Avian Influenza: Update. <i>Medical Principles and Practice</i> , 2010, 19, 421-432.	1.1	26
112	Antiviral therapy: quo vadis?. <i>Future Medicinal Chemistry</i> , 2010, 2, 1049-1053.	1.1	4

#	ARTICLE	IF	CITATIONS
113	In Vitro inhibitory activity of <i>Alpinia katsumadai</i> extracts against influenza virus infection and hemagglutination. <i>Virology Journal</i> , 2010, 7, 307.	1.4	55
114	Anti-Influenza Drug Discovery: Structure-Activity Relationship and Mechanistic Insight into Novel Angelicin Derivatives. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1519-1533.	2.9	139
115	Combination Chemotherapy for Influenza. <i>Viruses</i> , 2010, 2, 1510-1529.	1.5	60
116	An integrated bioinformatics approach to the characterization of influenza A/H5N1 viral sequences by microarray data: Implication for monitoring H5N1 emerging strains and designing appropriate influenza vaccines. <i>Molecular and Cellular Probes</i> , 2010, 24, 387-395.	0.9	3
117	C-Methylated Flavonoids from <i>Cleistocalyx operculatus</i> and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase. <i>Journal of Natural Products</i> , 2010, 73, 1636-1642.	1.5	88
118	Selective Binding of Antiinfluenza Drugs and Their Analogues to "Open" and "Closed" Conformations of H5N1 Neuraminidase. <i>Journal of Physical Chemistry B</i> , 2010, 114, 12958-12964.	1.2	17
119	Anti-Influenza Virus Compound from <i>Streptomyces</i> sp. RI18. <i>Organic Letters</i> , 2010, 12, 4664-4666.	2.4	19
120	Correlation Analyses on Binding Affinity of Sialic Acid Analogues with Influenza Virus Neuraminidase-1 Using ab Initio MO Calculations on Their Complex Structures. <i>Journal of Chemical Information and Modeling</i> , 2010, 50, 1796-1805.	2.5	38
121	Anti-influenza agents from Traditional Chinese Medicine. <i>Natural Product Reports</i> , 2010, 27, 1758.	5.2	106
122	Biotin-, fluorescein- and "clickable" conjugates of phospho-oseltamivir as probes for the influenza virus which utilize selective binding to the neuraminidase. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 5625.	1.5	10
123	Therapeutics Against Influenza. <i>Current Topics in Microbiology and Immunology</i> , 2011, 370, 273-300.	0.7	23
124	Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 239-254.	1.9	7
125	A Practical Synthesis of Zanamivir Phosphonate Congeners with Potent Anti-influenza Activity. <i>Journal of the American Chemical Society</i> , 2011, 133, 17959-17965.	6.6	83
126	Molecular Dynamics Simulation Directed Rational Design of Inhibitors Targeting Drug-Resistant Mutants of Influenza A Virus M2. <i>Journal of the American Chemical Society</i> , 2011, 133, 12834-12841.	6.6	127
127	Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza A Virus M2 Proton Channel. <i>Journal of the American Chemical Society</i> , 2011, 133, 13844-13847.	6.6	64
128	Discovery of Potential M2 Channel Inhibitors Based on the Amantadine Scaffold via Virtual Screening and Pharmacophore Modeling. <i>Molecules</i> , 2011, 16, 10227-10255.	1.7	20
129	Solid-Phase Synthesis of Mimosine Tetrapeptides and Their Inhibitory Activities on Neuraminidase and Tyrosinase. <i>Journal of Agricultural and Food Chemistry</i> , 2011, 59, 12858-12863.	2.4	26
130	Synthesis of Hemagglutinin-Binding Trisaccharides. <i>Advances in Experimental Medicine and Biology</i> , 2011, 705, 691-726.	0.8	4

#	ARTICLE	IF	CITATIONS
131	Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in Inhibitors of M2 from Influenza A Virus. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 307-312.	1.3	51
132	HIV-1 Integrase and Neuraminidase Inhibitors from <i>Alpinia zerumbet</i> . <i>Journal of Agricultural and Food Chemistry</i> , 2011, 59, 2857-2862.	2.4	56
133	A 40-Year Journey in Search of Selective Antiviral Chemotherapy*. <i>Annual Review of Pharmacology and Toxicology</i> , 2011, 51, 1-24.	4.2	145
134	Influenza in immunocompromised patients: considerations for therapy. <i>Future Virology</i> , 2011, 6, 855-868.	0.9	6
135	A water-swap reaction coordinate for the calculation of absolute protein-ligand binding free energies. <i>Journal of Chemical Physics</i> , 2011, 134, 054114.	1.2	73
136	From plant to drug: ionic liquids for the reactive dissolution of biomass. <i>Green Chemistry</i> , 2011, 13, 1442.	4.6	58
137	Correlation Analyses on Binding Affinity of Sialic Acid Analogues and Anti-Influenza Drugs with Human Neuraminidase Using ab Initio MO Calculations on Their Complex Structures - LERE-QSAR Analysis (IV). <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2706-2716.	2.5	35
138	Selection of an Antiviral RNA Aptamer Against Hemagglutinin of the Subtype H5 Avian Influenza Virus. <i>Nucleic Acid Therapeutics</i> , 2011, 21, 395-402.	2.0	47
140	Glycomic analysis of ovarian cancer: Past, present, and future. <i>Cancer Biomarkers</i> , 2011, 8, 273-280.	0.8	6
141	Novel Inhibitor Design for Hemagglutinin against H1N1 Influenza Virus by Core Hopping Method. <i>PLoS ONE</i> , 2011, 6, e28111.	1.1	99
142	A Novel Ribozyme-Based Prophylaxis Inhibits Influenza A Virus Replication and Protects from Severe Disease. <i>PLoS ONE</i> , 2011, 6, e27327.	1.1	17
143	Anti-Influenza Virus Activity of Tricin, 4,5,7-trihydroxy-3,5-dimethoxyflavone. <i>Antiviral Chemistry and Chemotherapy</i> , 2011, 22, 1-11.	0.3	30
144	Discovery of Dihydroalkoxybenzyl Oxypyrimidines as Promising Anti-Influenza Virus Agents. <i>Chemical Biology and Drug Design</i> , 2011, 78, 596-602.	1.5	6
145	Recent synthetic approaches to oseltamivir phosphate (Tamiflu,®) for the treatment of influenza. <i>Tetrahedron</i> , 2011, 67, 7875-7899.	1.0	64
146	Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules. <i>Antiviral Research</i> , 2011, 92, 64-72.	1.9	15
147	Molecular dynamics directed CoMFA studies on carbocyclic neuraminidase inhibitors. <i>Molecular Diversity</i> , 2011, 15, 979-987.	2.1	8
148	Discovery of highly potent agents against influenza A virus. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 52-57.	2.6	43
149	The many faces of the adamantyl group in drug design. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 1949-1963.	2.6	247

#	ARTICLE	IF	CITATIONS
150	Rapid and specific influenza virus detection by functionalized magnetic nanoparticles and mass spectrometry. <i>Journal of Nanobiotechnology</i> , 2011, 9, 52.	4.2	71
151	Lysosome-associated membrane glycoprotein 3 is involved in influenza A virus replication in human lung epithelial (A549) cells. <i>Virology Journal</i> , 2011, 8, 384.	1.4	32
153	Influenza A virus infection kinetics: quantitative data and models. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2011, 3, 429-445.	6.6	136
154	The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. <i>Medicinal Research Reviews</i> , 2011, 31, 118-160.	5.0	38
155	Enantioselective Total Synthesis of (+)-Stachyflin: A Potential Anti-Influenza A Virus Agent Isolated from a Microorganism. <i>European Journal of Organic Chemistry</i> , 2011, 2011, 2948-2957.	1.2	35
157	Dynamic One-Pot Three-Component Catalytic Asymmetric Transformation by Combination of Hydrogen-Bond Donating and Amine Catalysts. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 7624-7630.	7.2	78
158	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from <i>Glycyrrhiza inflata</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 294-298.	1.0	126
159	Synthesis and evaluation of quinoxaline derivatives as potential influenza NS1A protein inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3007-3011.	1.0	41
160	Uncovering the global host cell requirements for influenza virus replication via RNAi screening. <i>Microbes and Infection</i> , 2011, 13, 516-525.	1.0	84
161	Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques. <i>Infectious Disorders - Drug Targets</i> , 2011, 11, 64-93.	0.4	43
163	Novel hemagglutinin inhibitors for H1N1 influenza virus screening from TCM database. <i>Molecular Simulation</i> , 2011, 37, 361-368.	0.9	8
164	Identification of the Minimal Active Sequence of an Anti-Influenza Virus Peptide. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1810-1813.	1.4	20
165	Evaluation of a Set of C9 <i>N</i> -acyl Neu5Ac2en Mimetics as Viral Sialidase Selective Inhibitors. <i>International Journal of Medicinal Chemistry</i> , 2011, 2011, 1-7.	2.2	4
166	Anti-influenza viral effects of novel nuclear export inhibitors from <i>Valerianae Radix</i> and <i>Alpinia galanga</i> . <i>Drug Discoveries and Therapeutics</i> , 2011, 5, 26-31.	0.6	29
167	Antiviral Pharmacodynamics in Hollow Fibre Bioreactors. <i>Antiviral Chemistry and Chemotherapy</i> , 2011, 21, 183-192.	0.3	14
168	Caffeoylquinic Acids Are Major Constituents with Potent Anti-Influenza Effects in Brazilian Green Propolis Water Extract. <i>Evidence-based Complementary and Alternative Medicine</i> , 2011, 2011, 1-7.	0.5	33
169	Synthesis and Biological Evaluation of Analogs of Methyl Ursolate 3-O- β -Chacotrioside as H5N1 Viral Entry Inhibitors. <i>Journal of Carbohydrate Chemistry</i> , 2012, 31, 647-658.	0.4	3
170	Evaluation of the Antiviral Activity of a Green Tea Solution as a Hand-Wash Disinfectant. <i>Bioscience, Biotechnology and Biochemistry</i> , 2012, 76, 581-584.	0.6	10

#	ARTICLE	IF	CITATIONS
171	Intracytoplasmic Trapping of Influenza Virus by a Lipophilic Derivative of Aglycoristocetin. <i>Journal of Virology</i> , 2012, 86, 9416-9431.	1.5	31
172	Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity against Influenza A and B Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6009-6013.	1.4	38
173	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 7155-7159.	1.4	34
174	Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 20385-20390.	3.3	45
175	Consensus QSAR model for identifying novel H5N1 inhibitors. <i>Molecular Diversity</i> , 2012, 16, 513-524.	2.1	9
176	Viral enzymes containing magnesium: Metal binding as a successful strategy in drug design. <i>Coordination Chemistry Reviews</i> , 2012, 256, 3063-3086.	9.5	53
177	Long Time Scale GPU Dynamics Reveal the Mechanism of Drug Resistance of the Dual Mutant I223R/H275Y Neuraminidase from H1N1-2009 Influenza Virus. <i>Biochemistry</i> , 2012, 51, 4364-4375.	1.2	37
178	Design, Synthesis, and in Vitro Biological Evaluation of 1 <i>H</i> -1,2,3-Triazole-4-carboxamide Derivatives as New Anti-influenza A Agents Targeting Virus Nucleoprotein. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2144-2153.	2.9	125
179	Identification of a novel compound with antiviral activity against influenza A virus depending on PA subunit of viral RNA polymerase. <i>Microbes and Infection</i> , 2012, 14, 740-747.	1.0	29
180	Oral administration of patchouli alcohol isolated from <i>Pogostemonis Herba</i> augments protection against influenza viral infection in mice. <i>International Immunopharmacology</i> , 2012, 12, 294-301.	1.7	63
181	Development of Oseltamivir Phosphonate Congeners as Anti-influenza Agents. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8657-8670.	2.9	47
182	Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. <i>BioEssays</i> , 2012, 34, 1050-1059.	1.2	227
183	Enantioselective Palladium-Catalyzed [3 + 2] Cycloadditions of Trimethylenemethane with Nitroalkenes. <i>Organic Letters</i> , 2012, 14, 234-237.	2.4	51
184	Mutation-Induced Loop Opening and Energetics for Binding of Tamiflu to Influenza N8 Neuraminidase. <i>Journal of Physical Chemistry B</i> , 2012, 116, 6137-6149.	1.2	30
185	Design and synthesis of pinanamine derivatives as anti-influenza A M2 ion channel inhibitors. <i>Antiviral Research</i> , 2012, 96, 91-99.	1.9	53
186	Human viral diseases: what is next for antiviral drug discovery?. <i>Current Opinion in Virology</i> , 2012, 2, 572-579.	2.6	30
187	Screen Anti-influenza Lead Compounds That Target the PAC Subunit of H5N1 Viral RNA Polymerase. <i>PLoS ONE</i> , 2012, 7, e35234.	1.1	12
188	Methamphetamine Reduces Human Influenza A Virus Replication. <i>PLoS ONE</i> , 2012, 7, e48335.	1.1	12

#	ARTICLE	IF	CITATIONS
189	Use of electrospray ionization ion-trap tandem mass spectrometry and principal component analysis to directly distinguish monosaccharides. <i>Rapid Communications in Mass Spectrometry</i> , 2012, 26, 1259-1264.	0.7	14
190	Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6247-6252.	3.3	114
191	Transformation of D-Serine to Highly Functionalized Cyclohexenecarboxylates in Study of Oseltamivir Synthesis. <i>Journal of the Chinese Chemical Society</i> , 2012, 59, 426-435.	0.8	5
192	The Glycopolymer Code: Synthesis of Glycopolymers and Multivalent Carbohydrate-Lectin Interactions. <i>Macromolecular Rapid Communications</i> , 2012, 33, 742-752.	2.0	186
193	Synthesis of 4-alkyl-2-aryl-1,3-oxazole[5,4-d]pyrimidine-7(4H)-thiones and 6-alkyl-2-aryl-1,3-oxazole[5,4-d]pyrimidin-7(6H)-ones from 2-arylamino-3,3-dichloroacrylonitriles. <i>Russian Journal of General Chemistry</i> , 2012, 82, 739-743.	0.3	4
194	One-Step Catalytic Enantioselective Quaternary 5-Hydroxyproline Synthesis: An Asymmetric Entry to Highly Functionalized Quaternary Proline Derivatives. <i>Advanced Synthesis and Catalysis</i> , 2012, 354, 1156-1162.	2.1	16
196	Boronucleotides as Substrates/Binders for Human NMP Kinases: Enzymatic and Spectroscopic Evaluation. <i>ChemBioChem</i> , 2012, 13, 1605-1612.	1.3	8
197	A Novel Three-Component [3+2] Cycloannulation Process for the Rapid and Highly Stereoselective Synthesis of Pyrrolobenzoxazoles. <i>Chemistry - A European Journal</i> , 2012, 18, 4185-4189.	1.7	23
198	Anti-Influenza Drug Discovery: Identification of an Orally Bioavailable Quinoline Derivative through Activity- and Property-Guided Lead Optimization. <i>ChemMedChem</i> , 2012, 7, 1546-1550.	1.6	6
199	TamiGold™: phospho-oseltamivir-stabilised gold nanoparticles as the basis for influenza therapeutics and diagnostics targeting the neuraminidase (instead of the hemagglutinin). <i>MedChemComm</i> , 2012, 3, 1373.	3.5	16
200	GFP-expressing influenza A virus for evaluation of the efficacy of antiviral agents. <i>Journal of Microbiology</i> , 2012, 50, 359-362.	1.3	14
201	Curcuminoids from <i>Curcuma longa</i> and their inhibitory activities on influenza A neuraminidases. <i>Food Chemistry</i> , 2012, 134, 21-28.	4.2	75
202	Identification of novel virus inhibitors by influenza A virus specific reporter cell based screening. <i>Antiviral Research</i> , 2012, 93, 48-54.	1.9	17
203	Antiviral effects of <i>Psidium guajava</i> Linn. (guava) tea on the growth of clinical isolated H1N1 viruses: Its role in viral hemagglutination and neuraminidase inhibition. <i>Antiviral Research</i> , 2012, 94, 139-146.	1.9	64
204	Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2152-2157.	1.4	16
205	Xanthenes from <i>Polygala karensium</i> inhibit neuraminidases from influenza A viruses. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3688-3692.	1.0	45
206	Influenza neuraminidase. <i>Influenza and Other Respiratory Viruses</i> , 2012, 6, 245-256.	1.5	202
207	Catalytic Asymmetric anti-selective Nitroaldol Reaction En Route to Zanamivir. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 1644-1647.	7.2	54

#	ARTICLE	IF	CITATIONS
208	Conjugation to Polymeric Chains of Influenza Drugs Targeting M2 Ion Channels Partially Restores Inhibition of Drug-Resistant Mutants. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2450-2459.	1.6	6
209	Efficient synthesis of 3 H,3â€² H -spiro[benzofuran-2,1â€²-isobenzofuran]-3,3â€²-dione as novel skeletons specifically for influenza virus type B inhibition. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 534-544.	2.6	50
210	Inhibition of MAO â€•A and stimulation of behavioural activities in mice by the inactive prodrug form of the antiâ€•influenza agent oseltamivir. <i>British Journal of Pharmacology</i> , 2013, 169, 115-129.	2.7	22
211	Dynamics of Influenza Virus and Human Host Interactions During Infection and Replication Cycle. <i>Bulletin of Mathematical Biology</i> , 2013, 75, 988-1011.	0.9	26
212	Exploring Histidine Conformations in the M2 Channel Lumen of the Influenza A Virus at Neutral pH via Molecular Simulations. <i>Journal of Physical Chemistry Letters</i> , 2013, 4, 3067-3071.	2.1	14
213	Germacrone inhibits early stages of influenza virus infection. <i>Antiviral Research</i> , 2013, 100, 578-588.	1.9	62
214	Exploitation of the Catalytic Site and 150 Cavity for Design of Influenza A Neuraminidase Inhibitors. <i>Journal of Organic Chemistry</i> , 2013, 78, 10867-10877.	1.7	29
215	Targeting Botulinum A Cellular Toxicity: A Prodrug Approach. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7870-7879.	2.9	21
216	Inhibition of influenza virus internalization by (â€•)-epigallocatechin-3-gallate. <i>Antiviral Research</i> , 2013, 100, 460-472.	1.9	108
217	Analysis and Assay of Oseltamivir-Resistant Mutants of Influenza Neuraminidase via Direct Observation of Drug Unbinding and Rebinding in Simulation. <i>Biochemistry</i> , 2013, 52, 8150-8164.	1.2	22
218	A comprehensive map of the influenza A virus replication cycle. <i>BMC Systems Biology</i> , 2013, 7, 97.	3.0	97
219	Synthesis of oseltamivir and tamiphosphor from N-acetyl-d-glucosamine. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 7687.	1.5	20
220	Recent Progress in the Discovery of Neuraminidase Inhibitors as Anti-influenza Agents. <i>Annual Reports in Medicinal Chemistry</i> , 2013, , 249-263.	0.5	1
221	Dancing with chemical formulae of antivirals: A panoramic view (Part 2). <i>Biochemical Pharmacology</i> , 2013, 86, 1397-1410.	2.0	34
222	Inhibition of herpesvirus and influenza virus replication by blocking polymerase subunit interactions. <i>Antiviral Research</i> , 2013, 99, 318-327.	1.9	15
224	Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1315-1320.	3.3	204
225	Antivirals: Past, present and future. <i>Biochemical Pharmacology</i> , 2013, 85, 727-744.	2.0	115
226	Pandemic 2009 H1N1 Influenza A Virus Carrying a Q136K Mutation in the Neuraminidase Gene Is Resistant to Zanamivir but Exhibits Reduced Fitness in the Guinea Pig Transmission Model. <i>Journal of Virology</i> , 2013, 87, 1912-1915.	1.5	25

#	ARTICLE	IF	CITATIONS
227	Synthesis and Biological Evaluation of Purine 2-Fluoro-2-Deoxyribose ProTides as Anti-Influenza Virus Agents. <i>ChemMedChem</i> , 2013, 8, 415-425.	1.6	12
229	Chemical Probes for Drug-Resistance Assessment by Binding Competition (RABC): Oseltamivir Susceptibility Evaluation. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 366-370.	7.2	10
230	Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 411-426.	2.5	14
231	Discovery of adamantane based highly potent HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2532-2537.	1.0	36
232	Photodegradation and inhibition of drug-resistant influenza virus neuraminidase using anthraquinone-sialic acid hybrids. <i>Chemical Communications</i> , 2013, 49, 1169.	2.2	20
233	Sex Differences in Prophylaxis and Therapeutic Treatments for Viral Diseases. <i>Handbook of Experimental Pharmacology</i> , 2013, , 499-522.	0.9	21
234	Polyhydroxylated pyrrolidine and 2-oxapyrrolizidine as glycosidase inhibitors. <i>MedChemComm</i> , 2013, 4, 783.	3.5	8
235	Discovery of Novel Dual Inhibitors of the Wild-Type and the Most Prevalent Drug-Resistant Mutant, S31N, of the M2 Proton Channel from Influenza A Virus. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2804-2812.	2.9	88
236	Anti-influenza active and low toxic N-phenyl-substituted β -amidoamidines structurally related to natural antibiotic amidinomycin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2357-2361.	1.0	1
237	A Cutting-Edge View on the Current State of Antiviral Drug Development. <i>Medicinal Research Reviews</i> , 2013, 33, 1249-1277.	5.0	53
238	Sesquiterpenoids from <i>Curcuma wenyujin</i> with anti-influenza viral activities. <i>Phytochemistry</i> , 2013, 85, 122-128.	1.4	41
239	Matriptase Proteolytically Activates Influenza Virus and Promotes Multicycle Replication in the Human Airway Epithelium. <i>Journal of Virology</i> , 2013, 87, 4237-4251.	1.5	67
241	COMPUTATIONAL MODELING STUDY ON METABOLISM MECHANISM OF OSELTAMIVIR. <i>Journal of Theoretical and Computational Chemistry</i> , 2013, 12, 1350037.	1.8	0
242	Dual Myxovirus Screen Identifies a Small-Molecule Agonist of the Host Antiviral Response. <i>Journal of Virology</i> , 2013, 87, 11076-11087.	1.5	17
243	Design of multiligand inhibitors for the swine flu H1N1 neuraminidase binding site. <i>Advances and Applications in Bioinformatics and Chemistry</i> , 2013, 6, 47.	1.6	7
244	An Assay Suitable for High Throughput Screening of Anti-Influenza Drugs. <i>PLoS ONE</i> , 2013, 8, e54070.	1.1	5
245	Inhibition of Influenza A Virus Infection In Vitro by Peptides Designed In Silico. <i>PLoS ONE</i> , 2013, 8, e76876.	1.1	21
246	Influenza A Virus Multiplication and the Cellular SUMOylation System. , 0, , .		2

#	ARTICLE	IF	CITATIONS
247	Glycopolymer Code Based on Well-Defined Glycopolymers or Glyconanomaterials and Their Biomolecular Recognition. <i>Frontiers in Bioengineering and Biotechnology</i> , 2014, 2, 39.	2.0	33
248	Animal Models for Influenza Viruses: Implications for Universal Vaccine Development. <i>Pathogens</i> , 2014, 3, 845-874.	1.2	92
249	Synthesis and antiviral activity of bis-spirocyclic derivatives of rhodanine. <i>Russian Chemical Bulletin</i> , 2014, 63, 1130-1136.	0.4	17
250	2D IR spectroscopy reveals the role of water in the binding of channel-blocking drugs to the influenza M2 channel. <i>Journal of Chemical Physics</i> , 2014, 140, 235105.	1.2	23
251	An efficient screening system for influenza virus cap-dependent endonuclease inhibitors. <i>Journal of Virological Methods</i> , 2014, 202, 8-14.	1.0	7
252	Synthesis and anti-influenza virus activity of 4-oxo- or thioxo-4,5-dihydrofuro[3,4-c]pyridin-3(1H)-ones. <i>Antiviral Research</i> , 2014, 107, 66-75.	1.9	17
253	1,2,3-Triazole-containing derivatives of rupestonic acid: Click-chemical synthesis and antiviral activities against influenza viruses. <i>European Journal of Medicinal Chemistry</i> , 2014, 76, 245-255.	2.6	78
254	Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2236-2243.	1.4	29
255	Phosphonate Congeners of Oseltamivir and Zanamivir as Effective Anti-influenza Drugs: Design, Synthesis and Biological Activity. <i>Journal of the Chinese Chemical Society</i> , 2014, 61, 127-141.	0.8	12
256	Stereospecific Synthesis of β -Diamino Esters. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 725-730.	1.2	9
257	Assaying multiple restriction endonucleases functionalities and inhibitions on DNA microarray with multifunctional gold nanoparticle probes. <i>Biosensors and Bioelectronics</i> , 2014, 52, 118-123.	5.3	19
258	A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment. <i>Antiviral Research</i> , 2014, 104, 23-33.	1.9	26
259	Development of Novel Potent Orally Bioavailable Oseltamivir Derivatives Active against Resistant Influenza A. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 759-769.	2.9	77
260	New Small Molecule Entry Inhibitors Targeting Hemagglutinin-Mediated Influenza A Virus Fusion. <i>Journal of Virology</i> , 2014, 88, 1447-1460.	1.5	72
261	Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 1561.	1.5	18
262	High-throughput docking for the identification of new influenza A virus polymerase inhibitors targeting the PA α -PB1 protein α -protein interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 280-282.	1.0	29
263	Stereospecific synthetic approach towards Tamiflu using the Ramberg α -Backlund reaction from cysteine hydrochloride. <i>RSC Advances</i> , 2014, 4, 62281-62284.	1.7	6
264	Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. <i>Archives of Virology</i> , 2014, 159, 3269-3278.	0.9	102

#	ARTICLE	IF	CITATIONS
265	Macromolecular (pro)drugs in antiviral research. <i>Polymer Chemistry</i> , 2014, 5, 6407-6425.	1.9	30
266	Natural Antiviral Compounds. <i>Studies in Natural Products Chemistry</i> , 2014, 42, 195-228.	0.8	13
267	Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation. <i>Journal of Controlled Release</i> , 2014, 196, 197-207.	4.8	16
268	Discovery of Pentacyclic Triterpenoids as Potential Entry Inhibitors of Influenza Viruses. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10058-10071.	2.9	106
269	Synthetic mimics of carbohydrate-based anticancer vaccines: preparation of carbohydrate polymers bearing unimolecular trivalent carbohydrate ligands by controlled living radical polymerization. <i>RSC Advances</i> , 2014, 4, 47066-47075.	1.7	5
270	Large negatively charged organic host molecules as inhibitors of endonuclease enzymes. <i>Chemical Communications</i> , 2014, 50, 11404-11406.	2.2	12
271	Inhibitors of the human neuraminidase enzymes. <i>MedChemComm</i> , 2014, 5, 1067-1074.	3.5	31
272	In vitro anti-influenza A activity of interferon (IFN)- γ 1 combined with IFN- γ 2 or oseltamivir carboxylate. <i>Antiviral Research</i> , 2014, 111, 112-120.	1.9	21
273	Contributions of NanI Sialidase to Caco-2 Cell Adherence by <i>Clostridium perfringens</i> Type A and C Strains Causing Human Intestinal Disease. <i>Infection and Immunity</i> , 2014, 82, 4620-4630.	1.0	38
274	Ionic liquid solutions as extractive solvents for value-added compounds from biomass. <i>Green Chemistry</i> , 2014, 16, 4786-4815.	4.6	357
275	Discovery and SAR study of piperidine-based derivatives as novel influenza virus inhibitors. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 8048-8060.	1.5	8
276	Noninvasive Visualization of Respiratory Viral Infection Using Bioorthogonal Conjugated Near-Infrared-Emitting Quantum Dots. <i>ACS Nano</i> , 2014, 8, 5468-5477.	7.3	65
277	Combined 3D-QSAR, molecular docking, and molecular dynamics study on potent cyclohexene-based influenza neuraminidase inhibitors. <i>Monatshefte für Chemie</i> , 2014, 145, 1213-1225.	0.9	11
278	Molecular dynamics modeling the synthetic and biological polymers interactions pre-studied via docking. <i>Journal of Computer-Aided Molecular Design</i> , 2014, 28, 647-673.	1.3	8
279	Biomimetic Asymmetric Total Syntheses of Spirooliganones A and B. <i>Organic Letters</i> , 2014, 16, 3740-3743.	2.4	33
280	Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs. <i>Antiviral Research</i> , 2014, 109, 54-63.	1.9	17
281	Oseltamivir Analogues Bearing N-Substituted Guanidines as Potent Neuraminidase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3154-3160.	2.9	38
282	Synthesis of the 6-6-6 tricyclic skeleton of the anti-influenza A diterpene wickerol A. <i>Tetrahedron Letters</i> , 2014, 55, 2183-2186.	0.7	10

#	ARTICLE	IF	CITATIONS
283	Adsorption properties of biologically active derivatives of quaternary ammonium surfactants and their mixtures at aqueous/air interface II. Dynamics of adsorption, micelles dissociation and cytotoxicity of QDLS. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 119, 154-161.	2.5	7
284	Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 49-54.	1.0	14
285	Tamiphosphor monoesters as effective anti-influenza agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 81, 106-118.	2.6	25
286	Synthesis and Anti-influenza Activities of Novel Baicalein Analogs. <i>Chemical and Pharmaceutical Bulletin</i> , 2014, 62, 415-421.	0.6	17
287	Acidic Proton Modulation of a Stilbene-based Zwitterionic Sulfonic Acid in the Solid State: Mimicking a Biological Device. <i>Chemistry Letters</i> , 2014, 43, 299-301.	0.7	1
288	Antivirally Active Ribavirin Analogues – 4,5-disubstituted 1,2,3-triazole Nucleosides: Biological Evaluation against Certain Respiratory Viruses and Computational Modelling. <i>Antiviral Chemistry and Chemotherapy</i> , 2014, 23, 161-171.	0.3	41
289	Antiviral properties of cage compounds. New prospects. <i>Russian Chemical Bulletin</i> , 2015, 64, 1473-1496.	0.4	47
290	Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design. <i>Scientific Reports</i> , 2015, 5, 13194.	1.6	44
291	Novel Daidzein Analogs and Their In Vitro Anti-Influenza Activities. <i>Chemistry and Biodiversity</i> , 2015, 12, 685-696.	1.0	14
292	Isocyanides as Influenza A Virus Subtype H5N1 Wild-Type M2 Channel Inhibitors. <i>ChemMedChem</i> , 2015, 10, 1837-1845.	1.6	12
293	Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics. <i>Chemistry - A European Journal</i> , 2015, 21, 10616-10628.	1.7	92
294	Synthesis and Crystallographic Insight into the Structural Aspects of Some Novel Adamantane-Based Ester Derivatives. <i>Molecules</i> , 2015, 20, 18827-18846.	1.7	11
295	Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir. <i>PLoS ONE</i> , 2015, 10, e0131089.	1.1	17
296	Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV. <i>Chemical Science</i> , 2015, 6, 264-269.	3.7	25
297	Bakuchiol Is a Phenolic Isoprenoid with Novel Enantiomer-selective Anti-influenza A Virus Activity Involving Nrf2 Activation. <i>Journal of Biological Chemistry</i> , 2015, 290, 28001-28017.	1.6	48
298	An Odyssey in antiviral drug development – 50 years at the Rega Institute: 1964–2014. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 520-543.	5.7	14
299	Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3208-3219.	1.6	19
300	One-pot amination of cage hydrocarbons. <i>Russian Journal of Organic Chemistry</i> , 2015, 51, 1703-1709.	0.3	22

#	ARTICLE	IF	CITATIONS
301	A Virtual Screening Approach For Identifying Plants with Anti H5N1 Neuraminidase Activity. Journal of Chemical Information and Modeling, 2015, 55, 308-316.	2.5	43
302	Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit. Antimicrobial Agents and Chemotherapy, 2015, 59, 1569-1582.	1.4	159
303	Role of omega-3 PUFA-derived mediators, the protectins, in influenza virus infection. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 496-502.	1.2	56
304	Synthesis and Biological Evaluation of 2-oxo-5-pyrazine-3-carboxamide Nucleoside Analogues and Their Epimers as Inhibitors of Influenza A Viruses. Chemical Biology and Drug Design, 2015, 85, 245-252.	1.5	11
305	First synthesis of nitrosporeusines, alkaloids with multiple biological activities. Tetrahedron Letters, 2015, 56, 1252-1254.	0.7	10
306	Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Biopolymers, 2015, 104, 291-309.	1.2	57
307	Identification of camphor derivatives as novel M2 ion channel inhibitors of influenza A virus. MedChemComm, 2015, 6, 727-731.	3.5	22
308	Novel 1-(2-aryl-2-adamantyl)piperazine derivatives with antiproliferative activity. European Journal of Medicinal Chemistry, 2015, 93, 281-290.	2.6	25
309	Green chemistry approaches as sustainable alternatives to conventional strategies in the pharmaceutical industry. RSC Advances, 2015, 5, 26686-26705.	1.7	51
310	Gene silencing: a therapeutic approach to combat influenza virus infections. Future Microbiology, 2015, 10, 131-140.	1.0	16
311	Generation of a variety of stable Influenza A reporter viruses by genetic engineering of the NS gene segment. Scientific Reports, 2015, 5, 11346.	1.6	57
312	Bioaktivne molekule " policikliÄki derivati gvanidina. Kemija U Industriji, 2015, 64, 125-141.	0.2	0
313	Synthesis, anti-HIV activity and molecular modeling study of 3-aryl-6-adamantylmethyl-[1,2,4]triazolo[3,4- <i>b</i>][1,3,4]thiadiazole derivatives. Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences, 2015, 70, 609-616.	0.3	9
314	Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins. Chemistry of Heterocyclic Compounds, 2015, 51, 275-280.	0.6	18
315	Efficacy and safety of Ban-Lan-Gen granules in the treatment of seasonal influenza: study protocol for a randomized controlled trial. Trials, 2015, 16, 126.	0.7	15
316	Targeting Influenza A Virus RNA Promoter. Chemical Biology and Drug Design, 2015, 86, 663-673.	1.5	30
317	Discovery of a new class of antiviral compounds: Camphor imine derivatives. European Journal of Medicinal Chemistry, 2015, 105, 263-273.	2.6	75
318	Synthesis and inhibitory effects of novel pyrimido-pyrrolo-quinoxalinedione analogues targeting nucleoproteins of influenza A virus H1N1. European Journal of Medicinal Chemistry, 2015, 102, 477-486.	2.6	23

#	ARTICLE	IF	CITATIONS
319	Crucial role of PA in virus life cycle and host adaptation of influenza A virus. <i>Medical Microbiology and Immunology</i> , 2015, 204, 137-149.	2.6	19
320	Synthesis, DNA interaction and antimicrobial activities of three rimantadine analogues. <i>Journal of Luminescence</i> , 2015, 159, 128-133.	1.5	13
321	Highly Active Macromolecular Prodrugs Inhibit Expression of the Hepatitis C Virus Genome in the Host Cells. <i>Advanced Healthcare Materials</i> , 2015, 4, 65-68.	3.9	25
322	Discovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous Heterosubtypic Targeting that Hedge against Antiviral Resistance. <i>PLoS Computational Biology</i> , 2016, 12, e1004663.	1.5	1
323	A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. <i>PLoS Pathogens</i> , 2016, 12, e1005409.	2.1	49
324	Lewis Acid-Catalyzed [3+2] Cycloaddition of Donor-Acceptor Cyclopropanes and Enamines: Enantioselective Synthesis of Nitrogen-Functionalized Cyclopentane Derivatives. <i>Advanced Synthesis and Catalysis</i> , 2016, 358, 2053-2058.	2.1	46
325	1, 8-Cineol Protect Against Influenza-Virus-Induced Pneumonia in Mice. <i>Inflammation</i> , 2016, 39, 1582-1593.	1.7	74
326	A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action. <i>Reviews in Medical Virology</i> , 2016, 26, 242-250.	3.9	44
327	Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity. <i>Advanced Healthcare Materials</i> , 2016, 5, 534-540.	3.9	11
328	Discovery of Novel Pyrazole Derivatives as Potent Neuraminidase Inhibitors against Influenza H1N1 Virus. <i>Archiv Der Pharmazie</i> , 2016, 349, 168-174.	2.1	20
329	Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment. <i>BMC Infectious Diseases</i> , 2016, 16, 325.	1.3	3
330	Understanding the within-host dynamics of influenza A virus: from theory to clinical implications. <i>Journal of the Royal Society Interface</i> , 2016, 13, 20160289.	1.5	50
331	In silico screening of molecular imprinting prepolymerization systems: oseltamivir selective polymers through full-system molecular dynamics-based studies. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 4210-4219.	1.5	22
332	Chemical Genomics Identifies the PERK-Mediated Unfolded Protein Stress Response as a Cellular Target for Influenza Virus Inhibition. <i>MBio</i> , 2016, 7, e00085-16.	1.8	17
333	Antiviral Drugs. , 2016, , 687-736.		18
334	Targeting the Channel Activity of Viroporins. <i>Advances in Protein Chemistry and Structural Biology</i> , 2016, 104, 307-355.	1.0	28
335	Design and synthesis of 1,2,3-triazole-containing N -acyl zanamivir analogs as potent neuraminidase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 397-406.	2.6	26
336	Cutting back on the carbs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10228-10230.	3.3	1

#	ARTICLE	IF	CITATIONS
337	The inhibitory effect of dehydroepiandrosterone and its derivatives against influenza A virus in vitro and in vivo. <i>Archives of Virology</i> , 2016, 161, 3061-3072.	0.9	13
338	Targeted disruption of influenza A virus hemagglutinin in genetically modified mice reduces viral replication and improves disease outcome. <i>Scientific Reports</i> , 2016, 6, 23746.	1.6	12
339	A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities. <i>Scientific Reports</i> , 2016, 6, 22790.	1.6	15
340	Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel. <i>ACS Infectious Diseases</i> , 2016, 2, 726-733.	1.8	32
341	Antiviral activities of compounds from aerial parts of <i>Salvia plebeia</i> R. Br. <i>Journal of Ethnopharmacology</i> , 2016, 192, 398-405.	2.0	50
342	Orthogonal Sensing of Small Molecules Using a Modular Nanoparticle-Based Assay. <i>ChemNanoMat</i> , 2016, 2, 489-493.	1.5	5
343	Approved Antiviral Drugs over the Past 50 Years. <i>Clinical Microbiology Reviews</i> , 2016, 29, 695-747.	5.7	1,049
344	Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1207-1216.	2.9	45
345	Tools of gene transfer applied to the intracellular delivery of non-nucleic acid polyanionic drugs. <i>Chemical Communications</i> , 2016, 52, 889-891.	2.2	6
346	In vitro and in vivo mechanism of immunomodulatory and antiviral activity of Edible Bird's Nest (EBN) against influenza A virus (IAV) infection. <i>Journal of Ethnopharmacology</i> , 2016, 185, 327-340.	2.0	50
347	Antiviral phenolics from the leaves of <i>Cleistocalyx operculatus</i> . <i>FITOTERAPIA</i> , 2016, 110, 135-141.	1.1	30
348	A high-throughput screening system targeting the nuclear export pathway via the third nuclear export signal of influenza A virus nucleoprotein. <i>Virus Research</i> , 2016, 217, 23-31.	1.1	7
349	Leaching of Active Ingredients from Plants with Ionic Liquids. <i>Green Chemistry and Sustainable Technology</i> , 2016, , 135-165.	0.4	2
350	Protective effects of Yinhuapinggan granule on mice with influenza viral pneumonia. <i>International Immunopharmacology</i> , 2016, 30, 85-93.	1.7	12
351	Antiviral effects of Yinhuapinggan granule against influenza virus infection in the ICR mice model. <i>Journal of Natural Medicines</i> , 2016, 70, 75-88.	1.1	18
352	An electrochemiluminescence biosensor for endonuclease EcoRI detection. <i>Biosensors and Bioelectronics</i> , 2017, 89, 585-591.	5.3	12
353	Ionic-Liquid-Mediated Extraction and Separation Processes for Bioactive Compounds: Past, Present, and Future Trends. <i>Chemical Reviews</i> , 2017, 117, 6984-7052.	23.0	689
354	Ribavirin attenuates the respiratory immune responses to influenza viral infection in mice. <i>Archives of Virology</i> , 2017, 162, 1661-1669.	0.9	13

#	ARTICLE	IF	CITATIONS
355	Anti-influenza A Virus Activity of Dendrobine and Its Mechanism of Action. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 3665-3674.	2.4	79
356	Anti-influenza effects of <i>Ganoderma lingzhi</i> : An animal study. <i>Journal of Functional Foods</i> , 2017, 34, 224-228.	1.6	8
357	Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret). <i>Biomedicine and Pharmacotherapy</i> , 2017, 91, 393-401.	2.5	38
358	Development of a point-of-care diagnostic for influenza detection with antiviral treatment effectiveness indication. <i>Lab on A Chip</i> , 2017, 17, 332-340.	3.1	17
359	In vitro and in vivo characterization of a novel H1N1/2009 influenza virus reassortant with an NS gene from a highly pathogenic H5N1 virus, isolated from a human. <i>Archives of Virology</i> , 2017, 162, 2633-2642.	0.9	1
360	Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection. <i>Scientific Reports</i> , 2017, 7, 102.	1.6	41
361	Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546. <i>ACS Infectious Diseases</i> , 2017, 3, 330-335.	1.8	15
362	Investigational hemagglutinin-targeted influenza virus inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 63-73.	1.9	52
363	Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 206-214.	3.3	340
364	Combinations of 1,8- ϵ -cineol and oseltamivir for the treatment of influenza virus A (H3N2) infection in mice. <i>Journal of Medical Virology</i> , 2017, 89, 1158-1167.	2.5	17
365	NMR spectra of PB2 627, the RNA-binding domain in influenza A virus RNA polymerase that contains the pathogenicity factor lysine 627, and improvement of the spectra by small osmolytes. <i>Biochemistry and Biophysics Reports</i> , 2017, 12, 129-134.	0.7	2
366	Potent peptidic fusion inhibitors of influenza virus. <i>Science</i> , 2017, 358, 496-502.	6.0	135
367	Structure-based drug discovery for combating influenza virus by targeting the PA \leftrightarrow PB1 interaction. <i>Scientific Reports</i> , 2017, 7, 9500.	1.6	27
368	Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	8
369	Tandem intramolecular cyclisation/1,3-aryl shift in N-(4,4-diethoxybutyl)-1-arylmethanimines (Kazan) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.7	16
370	A sensitive and real-time assay of restriction endonuclease activity and inhibition based on photo-induced electron transfer. <i>Sensors and Actuators B: Chemical</i> , 2017, 252, 477-482.	4.0	6
371	Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3744-3748.	1.0	48
372	Macromolecular Prodrugs of Ribavirin: Structure \leftrightarrow Function Correlation as Inhibitors of Influenza Infectivity. <i>Molecular Pharmaceutics</i> , 2017, 14, 234-241.	2.3	14

#	ARTICLE	IF	CITATIONS
373	Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 661-670.	2.6	38
374	Pinanamine Is a Promising Lead Compound against Influenza A Virus: Evidence from <i>in Vitro</i> and <i>in Vivo</i> Efficacy Compared to Amantadine. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 954-959.	0.6	1
375	Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 2271-2285.	1.0	49
376	Cholinesterase Inhibitory Activities of Adamantyl-Based Derivatives and Their Molecular Docking Studies. <i>Molecules</i> , 2017, 22, 1005.	1.7	9
377	Emerging Roles of Heparanase in Viral Pathogenesis. <i>Pathogens</i> , 2017, 6, 43.	1.2	42
378	Complexes of Oligoribonucleotides with D-Mannitol Inhibit Hemagglutinin-Glycan Interaction and Suppress Influenza A Virus H1N1 (A/FM/1/47) Infectivity <i>In Vitro</i> . <i>Pharmaceuticals</i> , 2017, 10, 71.	1.7	8
379	Adamantane in Drug Delivery Systems and Surface Recognition. <i>Molecules</i> , 2017, 22, 297.	1.7	102
380	Evolution of Influenza A Virus by Mutation and Re-Assortment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1650.	1.8	225
381	Protective Effect of Panax notoginseng Root Water Extract against Influenza A Virus Infection by Enhancing Antiviral Interferon-Mediated Immune Responses and Natural Killer Cell Activity. <i>Frontiers in Immunology</i> , 2017, 8, 1542.	2.2	40
382	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 1802.	2.2	78
383	Antiviral Therapy. , 2017, , 367-381.		2
384	Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies. <i>Infection and Drug Resistance</i> , 2017, Volume 10, 215-226.	1.1	5
385	Profiling the <i>in vitro</i> drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. <i>Antiviral Research</i> , 2018, 153, 10-22.	1.9	19
386	A Negishi cross-coupling reaction enables the total synthesis of (+)-stachyflin. <i>Tetrahedron</i> , 2018, 74, 3348-3357.	1.0	11
387	Within-Host Evolution of Human Influenza Virus. <i>Trends in Microbiology</i> , 2018, 26, 781-793.	3.5	96
388	New thiazolyl-coumarin hybrids: Design, synthesis, characterization, X-ray crystal structure, antibacterial and antiviral evaluation. <i>Journal of Molecular Structure</i> , 2018, 1166, 147-154.	1.8	56
389	Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects. <i>Journal of Controlled Release</i> , 2018, 275, 53-66.	4.8	13
390	Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. <i>Medicinal Research Reviews</i> , 2018, 38, 951-976.	5.0	146

#	ARTICLE	IF	CITATIONS
391	Discovery of (E)-1-amino-4-phenylbut-3-en-2-ol derivatives as novel neuraminidase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2003-2007.	1.0	3
392	Development and Validation of a Method for Determination of a New Effective Inhibitor of Influenza Virus H1N1 in Blood Plasma. <i>Pharmaceutical Chemistry Journal</i> , 2018, 51, 1102-1105.	0.3	3
393	Cappariolide A shows antiviral and better anti-inflammatory effects against influenza virus via regulating host IFN signaling, in vitro and vivo. <i>Life Sciences</i> , 2018, 200, 115-125.	2.0	15
394	The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors. <i>Chemical Biology and Drug Design</i> , 2018, 91, 105-115.	1.5	2
395	Multivalent oleanolic acid human serum albumin conjugate as nonglycosylated neomucin for influenza virus capture and entry inhibition. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1723-1731.	2.6	25
396	Detection of Membrane Mechanical Properties and Endocytosis by Single Molecule Force Spectroscopy. , 2018, , 91-115.		0
397	Monosaccharide Derivatives with Low Nanomolar Lectin Affinity and High Selectivity Based on Combined Fluorine Amide, Phenyl Arginine, Sulfur, and Halogen Bond Interactions. <i>ChemMedChem</i> , 2018, 13, 133-137.	1.6	75
398	Drug-Repositioning Approach for the Discovery of Anti-Influenza Virus Activity of Japanese Herbal (Kampo) Medicines In Vitro: Potent High Activity of Daio-Kanzo-To. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-9.	0.5	6
399	In search of effective H1N1 neuraminidase inhibitor by molecular docking, antiviral evaluation and membrane interaction studies using NMR. <i>Acta Virologica</i> , 2018, 62, 179-190.	0.3	8
400	An active component containing pterodonic acid and pterodondiol isolated from <i>Lagdera pterodonta</i> inhibits influenza A virus infection through the TLR7/MyD88/TRAF6/NF- κ B signaling pathway. <i>Molecular Medicine Reports</i> , 2018, 18, 523-531.	1.1	5
401	Annexins in Influenza Virus Replication and Pathogenesis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1282.	1.6	17
402	Spirostaphylotrichin X from a Marine-Derived Fungus as an Anti-influenza Agent Targeting RNA Polymerase PB2. <i>Journal of Natural Products</i> , 2018, 81, 2722-2730.	1.5	47
403	Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 206-216.	2.6	12
404	Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function. <i>Journal of Virology</i> , 2018, 92, .	1.5	50
405	Back to the Future: Lessons Learned From the 1918 Influenza Pandemic. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 343.	1.8	195
406	Animal models used to assess influenza antivirals. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 1131-1139.	2.5	20
407	Antimicrobial Use and Ecotoxicological Risks from Pandemics and Epidemics. , 2018, , 149-165.		0
408	Biosensor for Rapid and Sensitive Detection of Influenza Virus. <i>Biotechnology and Bioprocess Engineering</i> , 2018, 23, 371-382.	1.4	28

#	ARTICLE	IF	CITATIONS
409	Synthesis of Trifluoromethylated, α,β -Unsaturated Lactones and Pyrazolinones and Discovery of Influenza Virus Polymerase Inhibitors. <i>ChemMedChem</i> , 2018, 13, 2390-2399.	1.6	9
410	Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3477-3482.	1.0	12
411	Untargeted search and identification of metabolites of antiviral agent camphecene in rat urine by liquid chromatography and mass spectrometry and studying their distribution in organs following peroral administration of the compound. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 161, 383-392.	1.4	8
412	Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5187-5198.	2.9	22
413	Complexes of Oligoribonucleotides with d-Mannitol Modulate the Innate Immune Response to Influenza A Virus H1N1 (A/FM/1/47) In Vivo. <i>Pharmaceuticals</i> , 2018, 11, 73.	1.7	5
414	A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase. <i>Viruses</i> , 2018, 10, 325.	1.5	15
415	Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers. <i>Antiviral Research</i> , 2018, 158, 147-160.	1.9	10
416	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 229-243.	2.6	19
417	Ionic liquid-based extraction and separation trends of bioactive compounds from plant biomass. <i>Separation Science and Technology</i> , 2019, 54, 559-579.	1.3	37
418	Design, synthesis of oleanolic acid-saccharide conjugates using click chemistry methodology and study of their anti-influenza activity. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111622.	2.6	22
419	Greater Efficacy of Black Ginseng (CJ EnerG) over Red Ginseng against Lethal Influenza A Virus Infection. <i>Nutrients</i> , 2019, 11, 1879.	1.7	18
420	Structure-aided optimization of 3-O- β -chacotriosyl ursolic acid as novel H5N1 entry inhibitors with high selective index. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 4048-4058.	1.4	7
421	Peptide Antiviral Strategies as an Alternative to Treat Lower Respiratory Viral Infections. <i>Frontiers in Immunology</i> , 2019, 10, 1366.	2.2	30
422	Role of neuromedin B and its receptor in the innate immune responses against influenza A virus infection in vitro and in vivo. <i>Veterinary Research</i> , 2019, 50, 80.	1.1	8
423	Fluorescent sialic derivatives for the specific detection of influenza viruses. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126773.	1.0	3
424	The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases. <i>Frontiers in Pharmacology</i> , 2019, 10, 1207.	1.6	119
425	p-STAT1 regulates the influenza A virus replication and inflammatory response in vitro and vivo. <i>Virology</i> , 2019, 537, 110-120.	1.1	19
426	Development of effective anti-influenza drugs: congeners and conjugates – a review. <i>Journal of Biomedical Science</i> , 2019, 26, 84.	2.6	78

#	ARTICLE	IF	CITATIONS
427	Impact of tetramerization on the ligand recognition of N1 influenza neuraminidase via MMGBSA approach. <i>Biopolymers</i> , 2019, 110, e23251.	1.2	1
428	Diamondoid Amino Acid-Based Peptide Kinase Inhibitor Analogues. <i>ChemMedChem</i> , 2019, 14, 663-672.	1.6	7
429	Antibody-free digital influenza virus counting based on neuraminidase activity. <i>Scientific Reports</i> , 2019, 9, 1067.	1.6	19
430	Structure-aided drug development of potential neuraminidase inhibitors against pandemic H1N1 exploring alternate binding mechanism. <i>Molecular Diversity</i> , 2019, 23, 927-951.	2.1	8
431	Synthesis and Biological Evaluation of NH ₂ -Sulfonyl Oseltamivir Analogues as Influenza Neuraminidase Inhibitors. <i>Molecules</i> , 2019, 24, 2176.	1.7	5
432	Synthesis of Chalcone Derivatives Containing Furan or/and Pyran Ring as Neuraminidase Inhibitors. <i>Chemical Research in Chinese Universities</i> , 2019, 35, 395-402.	1.3	2
433	A small-molecule fusion inhibitor of influenza virus is orally active in mice. <i>Science</i> , 2019, 363, .	6.0	98
434	The intersection of sex and gender in the treatment of influenza. <i>Current Opinion in Virology</i> , 2019, 35, 35-41.	2.6	60
435	Time-Resolved Systems Medicine Reveals Viral Infection-Modulating Host Targets. <i>Systems Medicine (New Rochelle, N Y)</i> , 2019, 2, 1-9.	1.4	14
436	Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial. <i>BMJ Open</i> , 2019, 9, e024800.	0.8	11
437	Iodine-catalyzed guanylation of amines with <i>N,N</i> -di-Boc-thiourea. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 9280-9283.	1.5	5
438	Effect of Forsythiaside A on the RLRs Signaling Pathway in the Lungs of Mice Infected with the Influenza A Virus FM1 Strain. <i>Molecules</i> , 2019, 24, 4219.	1.7	23
439	Living in the Fast Lane—High Throughput Controlled/Living Radical Polymerization. <i>Macromolecules</i> , 2019, 52, 3-23.	2.2	87
440	Virucidal nano-perforator of viral membrane trapping viral RNAs in the endosome. <i>Nature Communications</i> , 2019, 10, 185.	5.8	35
441	Study on cognitive load of OM interface and eye movement experiment for nuclear power system. <i>Nuclear Engineering and Technology</i> , 2020, 52, 78-86.	1.1	3
442	Polygalasaponin F treats mice with pneumonia induced by influenza virus. <i>Inflammopharmacology</i> , 2020, 28, 299-310.	1.9	12
443	Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo. <i>Virologica Sinica</i> , 2021, 36, 490-500.	1.2	24
444	An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18431-18438.	3.3	25

#	ARTICLE	IF	CITATIONS
445	Conjugation of 1-Aminoadamantanes and 5-Trifluoromethylhydantoins by 1,3-Dipolar Cycloaddition. <i>Russian Journal of General Chemistry</i> , 2020, 90, 1831-1835.	0.3	0
446	Development of High Dose Oseltamivir Phosphate Dry Powder for Inhalation Therapy in Viral Pneumonia. <i>Pharmaceutics</i> , 2020, 12, 1154.	2.0	4
447	A universal dual mechanism immunotherapy for the treatment of influenza virus infections. <i>Nature Communications</i> , 2020, 11, 5597.	5.8	15
448	Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression. <i>Scientific Reports</i> , 2020, 10, 7635.	1.6	40
449	In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. <i>Viruses</i> , 2020, 12, 581.	1.5	10
450	Synthetic Advancement of Neuraminidase Inhibitor "Tamiflu". <i>ChemistrySelect</i> , 2020, 5, 6083-6122.	0.7	6
451	[1,2]-Rearrangement of iminium salts provides access to heterocycles with adamantane scaffold. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 4941-4945.	1.5	7
452	Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6924-6940.	2.9	20
453	Signal-off tuned signal-on (SF-T-SN) colorimetric immunoassay for amantadine using activity-metalmodulated peroxidase-mimicking nanozyme. <i>Sensors and Actuators B: Chemical</i> , 2020, 311, 127933.	4.0	14
454	Deficiency of HIF-1 α enhances influenza A virus replication by promoting autophagy in alveolar type II epithelial cells. <i>Emerging Microbes and Infections</i> , 2020, 9, 691-706.	3.0	71
455	Anthralin Suppresses the Proliferation of Influenza Virus by Inhibiting the Cap-Binding and Endonuclease Activity of Viral RNA Polymerase. <i>Frontiers in Microbiology</i> , 2020, 11, 178.	1.5	2
456	Mesoscale All-Atom Influenza Virus Simulations Suggest New Substrate Binding Mechanism. <i>ACS Central Science</i> , 2020, 6, 189-196.	5.3	86
457	Influenza and pregnancy. <i>British Journal of Midwifery</i> , 2020, 28, 78-82.	0.1	0
458	Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers. <i>Pharmaceutics</i> , 2020, 12, 171.	2.0	143
459	Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3120-3130.	2.9	21
460	Anti-H1N1 viral activity of three main active ingredients from zedoary oil. <i>F\ddot{A}-toterap\ddot{A}-\ddot{A}</i> , 2020, 142, 104489.	1.1	16
461	A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs. <i>Viruses</i> , 2020, 12, 167.	1.5	7
462	A Multiligand Architectural Photosensitizer That Targets Hemagglutinin on Envelope of Influenza Virus for Photodynamic Inactivation. <i>Small</i> , 2020, 16, e2000556.	5.2	14

#	ARTICLE	IF	CITATIONS
463	Efficient one-pot, three-component procedure to prepare new $\hat{\pm}$ -aminophosphonate and phosphonic acid acyclic nucleosides. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 43-67.	0.4	11
464	An efficient synthesis of novel anti influenza viral and cytotoxic derivatives of	0.3	0
465	A new G-triplex-based strategy for sensitivity enhancement of the detection of endonuclease activity and inhibition. <i>RSC Advances</i> , 2021, 11, 28008-28013.	1.7	2
466	Synthesis of noradamantane derivatives by ring-contraction of the adamantane framework. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 4027-4031.	1.5	3
467	Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with <i>in vivo</i> antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses. <i>Emerging Microbes and Infections</i> , 2021, 10, 1832-1848.	3.0	10
468	Antiviral Activity of 3D, a Butene Lactone Derivative Against Influenza A Virus In Vitro and In Vivo. <i>Viruses</i> , 2021, 13, 278.	1.5	3
469	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 172, 524-541.	3.6	123
470	Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 865-875.	1.5	19
471	The matrix gene of pdm/09 H1N1 contributes to the pathogenicity and transmissibility of SIV in mammals. <i>Veterinary Microbiology</i> , 2021, 255, 109039.	0.8	10
472	Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle. <i>Journal of Virology</i> , 2021, 95, .	1.5	14
473	Antiviral Activity of Isoimperatorin Against Influenza A Virus in vitro and its Inhibition of Neuraminidase. <i>Frontiers in Pharmacology</i> , 2021, 12, 657826.	1.6	16
474	Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo. <i>Scientific Reports</i> , 2021, 11, 9427.	1.6	7
475	Antiviral Activity Exerted by Natural Products against Human Viruses. <i>Viruses</i> , 2021, 13, 828.	1.5	74
476	A sequential multicomponent reaction (SMCR) strategy: Synthesis of novel pyrazolo-1,4-dioxaspiro[4,5]decane grafted spiro-indenoquinoxaline pyrrolidine heterocycles. <i>Synthetic Communications</i> , 0, , 1-14.	1.1	2
477	Substantial effect of phytochemical constituents against the pandemic disease influenza—a review. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 120.	1.1	6
478	Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections. <i>Bioconjugate Chemistry</i> , 2021, 32, 1548-1553.	1.8	9
479	Sensitivity of influenza virus strains isolated from various regions of Kazakhstan in 2018–2019 to antiviral drugs. <i>Klinicheskaia Meditsina</i> , 2021, 99, 276-281.	0.2	0
480	Application of Nanomaterials as an Advanced Strategy for the Diagnosis, Prevention, and Treatment of Viral Diseases. <i>Pharmaceutics</i> , 2021, 13, 1570.	2.0	17

#	ARTICLE	IF	CITATIONS
481	Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113591.	2.6	7
482	Bleomycin-Fe(II) agent with potentiality for treating drug-resistant H1N1 influenza virus: A study using electrochemical RNA beacons. <i>Analytica Chimica Acta</i> , 2021, 1180, 338862.	2.6	2
483	Discovery of novel thiophene derivatives as potent neuraminidase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113762.	2.6	10
484	<i>Lung Disease.</i> , 2021, , 595-640.		0
485	Selected \hat{I}^{22} -, \hat{I}^{23} - and $\hat{I}^{22,3}$ -Amino Acid Heterocyclic Derivatives and Their Biological Perspective. <i>Molecules</i> , 2021, 26, 438.	1.7	8
486	Distribution and evolution of H1N1 influenza A viruses with adamantanes-resistant mutations worldwide from 1918 to 2019. <i>Journal of Medical Virology</i> , 2021, 93, 3473-3483.	2.5	18
487	<i>Plant-derived natural products as leads for drug discovery.</i> , 2009, , 547-567.		9
488	Molecular-Level Simulation of Pandemic Influenza Glycoproteins. <i>Methods in Molecular Biology</i> , 2012, 819, 575-594.	0.4	7
489	<i>Sex Differences in Influenza Virus Infection, Vaccination, and Therapies.</i> , 2015, , 183-210.		8
490	The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern. <i>Journal of General Virology</i> , 2016, 97, 1311-1323.	1.3	12
491	<i>Influenza Virus Antiviral Targets.</i> , 0, , 187-207.		5
492	Therapeutic targets for influenza â€™ perspectives in drug development. <i>Collection of Czechoslovak Chemical Communications</i> , 2010, 75, 81-103.	1.0	3
493	HopPER: an adaptive model for probability estimation of influenza reassortment through host prediction. <i>BMC Medical Genomics</i> , 2020, 13, 9.	0.7	12
494	Safety and Immunogenicity of H5N1 Influenza Vaccine Based on Baculovirus Surface Display System of <i>Bombyx mori</i> . <i>PLoS ONE</i> , 2008, 3, e3933.	1.1	42
495	Anti-Influenza Activity of Marchantins, Macrocyclic Bisbibenzyls Contained in Liverworts. <i>PLoS ONE</i> , 2011, 6, e19825.	1.1	73
496	Potent Host-Directed Small-Molecule Inhibitors of Myxovirus RNA-Dependent RNA-Polymerases. <i>PLoS ONE</i> , 2011, 6, e20069.	1.1	39
497	Anti-Influenza Activity of C60 Fullerene Derivatives. <i>PLoS ONE</i> , 2013, 8, e66337.	1.1	59
498	Comparative Analysis of Seven Viral Nuclear Export Signals (NESs) Reveals the Crucial Role of Nuclear Export Mediated by the Third NES Consensus Sequence of Nucleoprotein (NP) in Influenza A Virus Replication. <i>PLoS ONE</i> , 2014, 9, e105081.	1.1	15

#	ARTICLE	IF	CITATIONS
499	INFLUENCE ON CELLULAR TARGETS FOR TREATING INFLUENZA INFECTION. Russian Journal of Infection and Immunity, 2014, 4, 15.	0.2	2
500	Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza: results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial. Oncotarget, 2017, 8, 55176-55186.	0.8	10
501	NEURAMINIDASE INHIBITORS – THE GOLD STANDARD OF ANTIVIRAL INFLUENZA A THERAPY. Meditsinskiy Sovet, 2017, , 25-30.	0.1	3
502	Nucleic Acids as Therapeutic Agents. Current Topics in Medicinal Chemistry, 2008, 8, 1379-1404.	1.0	89
503	Quantitative Methods for Testing Antiviral Activities of Textile Fabrics. Journal of Antimicrobial Agents, 2017, 03, .	0.2	5
504	An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus. BMB Reports, 2008, 41, 640-644.	1.1	19
505	Conjunction of factors triggering waves of seasonal influenza. ELife, 2018, 7, .	2.8	35
506	Clinical Use of Tamiflu (Oseltamivir). Journal of the Korean Medical Association, 2008, 51, 757.	0.1	1
507	Virus- und Prion-Infektionen. , 2009, , 567-585.		0
508	Modes of action. , 2010, , 10-23.		2
509	Synthesis and Antiviral Evaluation of Bisnoradamantane Sulfites and Related Compounds. Medicinal Chemistry, 2011, 7, 135-140.	0.7	0
511	Novel Carbohydrate-Based Inhibitors That Target Influenza A Virus Sialidase. , 2012, , 261-267.		0
513	Information Gain based Methodology to Predict the Effect of Conformational Change on the Existence of f10 Epitope on the Surface of Human H5N1 Virus Hemagglutinin Protein. International Journal of Computer Applications, 2013, 67, 34-41.	0.2	0
514	Examples of Applications of Electrophysiology. , 2016, , 119-138.		0
517	Moderne Anwendungsbeispiele aus der Elektrophysiologie. , 2018, , 135-158.		0
519	Tetraspanins: Host Factors in Viral Infections. International Journal of Molecular Sciences, 2021, 22, 11609.	1.8	27
520	The Evolutionary Significance of Generalist Viruses with Special Emphasis on Plant Viruses and their Hosts. The Open Virology Journal, 2020, 14, 22-29.	1.8	2
522	Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study. Open Forum Infectious Diseases, 2021, 8, ofaa562.	0.4	7

#	ARTICLE	IF	CITATIONS
523	2018–2019 antiviral drug sensitivity of the influenza virus strains isolated from various regions of Kazakhstan. Russian Journal of Infection and Immunity, 2022, 11, 1159-1166.	0.2	0
524	A Molecular Docking Study of Peramivir and Zanamivir as Potential Inhibitors of the H1N1 Influenza Target Protein. International Journal of Pharma and Bio Sciences, 2022, 13, 73-79.	0.1	0
525	Reduction of some viral protein's gene expression of recombinant influenza A/H1N1-PR8 virus upon treatment with Punica granatum crude extract. Gene Reports, 2022, 26, 101524.	0.4	1
526	Anti-influenza patchoulol-type sesquiterpenoids from Pogostemon cablin. Phytochemistry Letters, 2022, 48, 34-39.	0.6	1
529	Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp). Journal of Medicinal Chemistry, 2022, 65, 3814-3832.	2.9	10
530	Chrysin Ameliorates Influenza Virus Infection in the Upper Airways by Repressing Virus-Induced Cell Cycle Arrest and Mitochondria-Dependent Apoptosis. Frontiers in Immunology, 2022, 13, 872958.	2.2	9
531	Synthesis, molecular docking of 3-(2-chloroethyl)-2,6-diphenylpiperidin-4-one: Hirshfeld surface, spectroscopic and DFT based analyses. Journal of Molecular Structure, 2022, 1262, 132993.	1.8	24
532	The inhibition effects and mechanisms of sulfated chitoooligosaccharides on influenza A virus in vitro and in vivo. Carbohydrate Polymers, 2022, 286, 119316.	5.1	6
533	Reusable Cu ₂ -xS-modified masks with infrared lamp-driven antibacterial and antiviral activity for real-time personal protection. Chemical Engineering Journal, 2022, 441, 136043.	6.6	13
534	Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA–PB1 Interaction. Journal of Medicinal Chemistry, 2022, 65, 369-385.	2.9	4
538	Influenza antivirals and animal models. FEBS Open Bio, 2022, 12, 1142-1165.	1.0	18
539	Discovery and pharmacodynamic evaluation of the novel butene lactone derivative <i>M355</i> against influenza A virus in vitro and in vivo. Journal of Medical Virology, 2022, 94, 4393-4405.	2.5	1
540	A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2. Frontiers in Microbiology, 2022, 13, .	1.5	10
541	Screening and purification of NanB sialidase from Pasteurella multocida with activity in hydrolyzing sialic acid Neu5Ac1±(2–6)Gal and Neu5Ac1±(2–3)Gal. Scientific Reports, 2022, 12, .	1.6	6
542	Baloxavir Marboxil Shows Anomalous Conversion of Crystal Forms from Stable to Metastable through Formation of Specific Solvate Form. Journal of Pharmaceutical Sciences, 2023, 112, 158-165.	1.6	2
543	Assembly of Poly(ethylene glycol)ylated Oleanolic Acid on a Linear Polymer as a Pseudomucin for Influenza Virus Inhibition and Adsorption. Biomacromolecules, 2022, 23, 3213-3221.	2.6	5
544	Binding mechanism of oseltamivir and influenza neuraminidase suggests perspectives for the design of new anti-influenza drugs. PLoS Computational Biology, 2022, 18, e1010343.	1.5	2
545	Nanoparticles in clinical trials of COVID-19: An update. International Journal of Surgery, 2022, 104, 106818.	1.1	22

#	ARTICLE	IF	CITATIONS
546	Nanocarriers as delivery tool for COVID-19 drugs. , 2022, , 293-332.		1
547	Modulating cholesterol-rich lipid rafts to disrupt influenza A virus infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
548	Alkyl Radical Generation via C=C Bond Cleavage in 2-Substituted Oxazolidines. <i>ACS Catalysis</i> , 2022, 12, 12469-12476.	5.5	6
549	Berberine ameliorates pulmonary inflammation in mice with influenza viral pneumonia by inhibiting NLRP3 inflammasome activation and gasdermin D-mediated pyroptosis. <i>Drug Development Research</i> , 2022, 83, 1707-1721.	1.4	7
550	In silico characterization of aryl benzoyl hydrazide derivatives as potential inhibitors of RdRp enzyme of H5N1 influenza virus. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
551	Annulated carbamates are precursors for the ring contraction of the adamantane framework. <i>RSC Advances</i> , 2022, 12, 31056-31060.	1.7	3
552	Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs. <i>RSC Advances</i> , 2022, 12, 31032-31045.	1.7	5
553	Inhibition of H1N1 by <i>Picochlorum</i> sp. 122 via AKT and p53 signaling pathways. <i>Food Science and Nutrition</i> , 0, , .	1.5	1
554	Optimization and SAR research at the benzoxazole and tetrazole rings of JNJ4796 as new anti-influenza A virus agents, part 2. <i>European Journal of Medicinal Chemistry</i> , 2023, 245, 114906.	2.6	1
555	Anti-influenza agents. , 2023, , 211-239.		0
556	Novel [1,2,4]triazolo[3,4-b][1,3,4]thiadiazine and [1,2,4]triazolo[3,4-b][1,3,4]thiadiazepine Derivatives: Synthesis, Anti-Viral In Vitro Study and Target Validation Activity. <i>Molecules</i> , 2022, 27, 7940.	1.7	5
557	Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update. <i>International Journal of Biological Macromolecules</i> , 2023, 229, 70-80.	3.6	7
558	Structurally various p-terphenyls with neuraminidase inhibitory from a sponge derived fungus <i>Aspergillus</i> sp. SCSIO41315. <i>Bioorganic Chemistry</i> , 2023, 132, 106357.	2.0	2
559	Therapeutic Targeting of Inflammation and Virus Simultaneously Ameliorates Influenza Pneumonia and Protects from Morbidity and Mortality. <i>Viruses</i> , 2023, 15, 318.	1.5	4
560	Burgeoning therapeutic strategies to curb the contemporary surging viral infections. <i>Microbial Pathogenesis</i> , 2023, 179, 106088.	1.3	0
561	Challenges Based on Antiplasmodial and Antiviral Activities of 7-Chloro-4-aminoquinoline Derivatives. <i>ChemMedChem</i> , 2023, 18, .	1.6	0
562	Antiviral Effect of Ginsenosides rk1 against Influenza a Virus Infection by Targeting the Hemagglutinin 1-Mediated Virus Attachment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4967.	1.8	1
563	Therapeutic potential of salicylamide derivatives for combating viral infections. <i>Medicinal Research Reviews</i> , 2023, 43, 897-931.	5.0	2

#	ARTICLE	IF	CITATIONS
564	Antiviral drugs and vaccines. , 2023, , 319-359.		1
575	Antiviral Veterinary Drugs Used to Treat Influenza. , 2024, , 441-448.		0
578	Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control. Journal of Nanoparticle Research, 2023, 25, .	0.8	0
584	Overcoming barriers with non-covalent interactions: supramolecular recognition of adamantyl cucurbit[<i>n</i>]uril assemblies for medical applications. RSC Medicinal Chemistry, 2024, 15, 433-471.	1.7	0